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ABSTRACT 
Background: Electroconvulsive Therapy (ECT) is still being administered to approximately 
a million people annually. There have been no ECT vs simulated ECT (SECT) studies since 
1985. The five meta-analyses of ECT vs SECT studies all claim that ECT is more effective 
than SECT for its primary target, severe depression. This review assesses the quality of those 
meta-analyses and of the 11 studies on which they are based. 
Methods: The meta-analyses were evaluated primarily in terms of whether they considered 
the quality of the studies they included, but also in terms of whether they addressed efficacy 
beyond end of treatment. The methodological rigour of the 11 studies included by one or 
more of the meta-analyses was assessed using a 24-point Quality scale developed for this 
review.   
Results: The five meta-analyses include between one and seven of the 11 studies. The meta-
analyses pay little or no attention to the multiple limitations of the studies they include. The 
11 studies have a mean Quality score of 12.3 out of 24. Eight scored 13 or less. Only four 
studies describe their processes of randomisation and testing the blinding. None convincingly 
demonstrate that they are double-blind. Five selectively report their findings. Only four report 
any ratings by patients. None assess Quality of Life. The studies are small, involving an 
average of 37 people. Four of the 11 found ECT significantly superior to SECT at the end of 
treatment, five found no significant difference and two found mixed results (including one 
where the psychiatrists reported a difference but patients did not). Only two higher Quality 
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studies report follow up data, one produced a near-zero effect size (.065) in the direction of 
ECT, and the other a small effect size (.299) in favour of SECT.  
Conclusions: The quality of most SECT-ECT studies is so poor that the meta-analyses were 
wrong to conclude anything about efficacy, either during or beyond the treatment period. 
There is no evidence that ECT is effective for its target demographic – older women, or its 
target diagnostic group – severely depressed people, or for suicidal people, people who have 
unsuccessfully tried other treatments first, involuntary patients, or adolescents. Given the 
high risk of permanent memory loss and the small mortality risk, this longstanding failure to 
determine whether or not ECT works means that its use should be immediately suspended 
until a series of well designed, randomised, placebo controlled studies have investigated 
whether there really are any significant benefits against which the proven significant risks can 
be weighed. 
 
Keywords: electroconvulsive therapy, depression, suicide, placebo, efficacy, meta-analyses, 
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INTRODUCTION 
Electroconvulsive therapy is still used on approximately a million people annually (Leiknes, 
Jarosh-von Schweder, & Hoie, 2012; Read, Bentall, Johnstone, Fosse, & Bracken, 2013). A 
review of 70 studies found, however, ‘large variation between continent, countries and 
regions in utilization, rates and clinical practice’ (Leiknes et al., p. 296). For instance, a 
recent audit found a 12-fold difference in usage between the highest and lowest using regions 
of England (Read, Harrop, Geekie, & Renton, 2018).  
The many recent studies that either compare ECT to other treatments, or compare different 
types of ECT with each other (Read & Arnold, 2018), typically open with an unqualified 
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statement that ECT is a very effective treatment for depression. Some may consider these 
types of studies sufficient to justify the use of ECT. We contend, however, that, ECT must be 
assessed using the same standards applied to psychiatric medications and other medical 
interventions, with placebo-controlled studies as the primary method for assessment.  
There have, however, only ever been 11 placebo-controlled studies of the efficacy of ECT. 
The last study comparing ECT with sham/simulated ECT (SECT), in which the general 
anaesthetic is administered but the electricity is not, was 34 years ago (Gregory, Shawcross, 
& Gill, 1985). This review evaluates, for the first time, the impartiality and robustness of the 
meta-analyses of this small body of literature, and the quality of the studies cited in the meta-
analyses. The primary goal is not to assess whether or not ECT is effective. The intent, 




A Medline (MESH) search for meta-analyses on the effectiveness of ECT for depression 
using placebo controlled trials (ECT vs SECT), was conducted in June 2019, using the 
following index terms: [‘electroconvulsive therapy’ OR ‘electroshock therapy’ OR 
‘electroconvulsive treatment’ OR ‘electroshock treatment’] AND [‘meta-analysis’] AND 
[‘depression’ OR ‘major depressive disorder’]. 
A 24-point Quality scale was developed to assess the studies cited by the meta-analyses. 
The scale combined the ‘risk of bias’ domains of the Cochrane Handbook Risk of Bias Tool 
(randomisation, blinding, incomplete outcome data and selective reporting) (Higgins & 
Green, 2011) with other criteria relating to quality of design and reporting, and some criteria 
specific to ECT research (see Table 1 for criteria and their definitions). No differential 
weightings were given to individual items, but the three key issues of randomisation, blinding 
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and diagnosis carried extra weight by virtue of having two or three items each. The 11 studies 
were independently rated, using the definitions in Table 1, by JR and LM, with each rater 
blind to the other’s ratings. ‘Yes’ indicated clear affirmative evidence. ‘No’ meant either no 
evidence or clear negative evidence. Inconsistencies between raters were resolved by 
discussion and re-reading the articles together. Spearman rank correlations and two-tailed t-
tests were used to assess the relationships between Quality scores and other variables. 
- - Table 1 about here - - 
 
RESULTS 
The search for meta-analyses produced 83 papers (see Figure 1). When the 83 papers were 
limited to [‘simulated ECT’ OR ‘sham ECT’] etc., 14 remained. Three of these were 
literature reviews (Greenhalgh, Knight, Hind, Beverley, & Walters, 2005; Read & Bentall, 
2010; Ross, 2006), one was a meta-analysis in Hungarian (Gábor & László, 2005), one was a 
meta-analysis of ECT vs SECT for older people only, discussed later (van der Wurff, Stek, 
Hooogendijk, & Beekman, 2003), and three were about transcranial magnetic stimulation. 
This left five meta-analyses for review (Janicak et al., 1985; Kho, van Vreewijk,  Simpson, & 
Zwinderman, 2003; Mutz et al., 2019; Pagnin, de Queiroz,  Pini, & Cassano, 2004; UK ECT 
Group, 2004). A follow up search in October 2019 found no further meta-analyses. 
- - Figure 1 about here - - 
Independent Quality Ratings 
The mean Quality scores of the two raters, for the 11 studies, 10.27 (sd 2.45) and 11.91 (sd 
2.91), were not significantly different (t (20) = 1.42, p = .17). Their scores for the 11 studies 
were significantly correlated (rho = .87, p = .001). There were 55 inconsistencies out of the 
264 ratings, representing an agreement rate of 79.2%. This translates to a kappa score (which 
allows for agreement by chance) of 0.58, in the ‘fair to good’ range (.40 - .75) (Fleiss, 1981). 
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The inconsistencies were resolved by discussion. The majority had resulted from raters 
missing (or misunderstanding) some text; for example, missing methodological information 
mentioned in a Results section, or results in a Discussion section. During this re-reading of 
studies together some instances where both raters had missed some quality evidence were 
also discovered, and scores increased accordingly.  
If ambiguity remained after discussion the raters erred on the side of ‘Yes’. For example, 
one rater rated Lambourn & Gill ‘No’ for ‘Means & SDs’, whereas the other rated it ‘Yes’ 
because the means were provided and the SDs, although not reported, could be calculated 
from individuals’ data. This was finalised as ‘Yes’. Brandon et al. reported means and SDs 
but only in the form of a graph, with no numbers, leading one rater to rate it as a ‘No’. After 
discussion, a ‘Yes’ was agreed. One rater had scored Ulett et al. as ‘No’ for ‘Reliable 
diagnosis’ because it was not explicitly stated that diagnoses made in the study were 
independent; but a 'Yes' was agreed on as there were two people diagnosing participants.  
The mean of the final, agreed, scores was 12.27 (sd 3.20), somewhat higher than the 
original means of the raters.   
 
The Eleven SECT vs ECT Studies Included in the Five Meta-Analyses: Findings at the 
end of Treatment 
The 11 ECT vs SECT studies for depression cited by one or more of the five meta-analyses, 
summarised in Table 2, are the only 11 ever conducted. None since 1985 have been identified 
by reviews (Read & Bentall, 2010; Read & Arnold, 2017) or the recent meta-analysis (Mutz, 
Vipulananthan, Carter, Hurlemann, Fu, & Young, 2019).  The first five were published 
between 1956 and 1963; with a second wave, of six, between 1978 and 1985. Three took 
place in the USA and the other eight in the UK, including all six of the later wave. So there 
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have been no such studies in the UK for 34 years, none in the USA for 56 years, and none 
anywhere else ever. 
- - Tables 2 & 3 about here  - - 
Ulett et al. (1956) - Quality Score 10/24.   The first SECT vs ECT study, conducted in the 
USA, compared both ECT and ‘convulsive photoshock’ (using flashing lights) to a sham 
treatment involving the same ‘light stage of sleep’ as the two treatment groups. There was no 
significant difference between the ECT and SECT groups on the psychiatrist’s ratings, with 
33% and 24% respectively showing ‘recovery or marked improvement’.  
This study, however, does not belong in an evaluation of ECT for depression. The 
participants were ‘individuals with the types of mental illness which are thought to respond 
best to the shock therapies’, in 1956. So 24 of the 42 (62%) in the ECT and SECT groups had 
diagnoses of ‘schizophrenic reaction’ or ‘involutional psychotic reaction’. The study also had 
no depression outcome measure. Despite this, and numerous other failings (see Table 3) two 
meta-analyses (Janicak et al., 1985; Pagnin et al., 2004) include this study. Pagnin and 
colleagues correctly report the difference between ECT and SECT as nonsignificant. The 
Janicak meta-analysis, however, wrongly report a significant difference in favour of shock 
therapy, by inappropriately merging the photoshock and ECT data.  
 
Brill et al. (1959) – 9/24.  The second study, also in the USA, did not assess outcome until a 
month after the treatment period so it really belongs as much with the  follow-up studies (see 
below) as with the short-term/end of treatment studies. The study was included in the same 
two meta-analyses as the Ulett study. It involved 97 men with an average age of 35, so was 
unrepresentative of the modal ECT recipient – a woman in her 60s (Leiknes et al., 2012; 
Read et al., 2013; 2018).  Only 30 were diagnosed with depression, but fortunately their data 
were reported separately. A positive outcome was deemed to be ‘recovery’ on two out of 
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three tools: ‘psychiatric evaluation, the Lorr Psychiatric Rating Scale, and psychological 
testing’. None of the three explicitly assessed depression.  
‘Nearly half’ of the participants had had ECT before, which may have contributed to the 
fact that ‘some patients in the nonshock group believed that they were receiving some new 
variation of ECT’ (p. 628). This raises the possibility that some could tell that they may not 
have had real ECT, because of the absence of headaches and confusion immediately 
afterwards.  
Sixteen of the 21 men in the ECT group (76%) and 4 of the 9 in the SECT group (44%) 
met the two-out-of-three criterion for recovery. The difference is not statistically significant.  
 
Harris & Robin (1960) – 9/24.  The first U.K. study was a trial of the antidepressant 
phenelzine, but included four women receiving ECT and four receiving SECT (all without 
phenelzine). The study invalidated any findings on ECT by giving ECT to the SECT group 
after four ECTs (two weeks). Despite this, and multiple other flaws (see Table 3), this study 
was included in two meta-analyses (Janicak et al., 1985; Pagnin et al., 2004). At the two 
week point two of the four ECT recipients and none of the SECT group had shown ‘great 
improvement’. This slight advantage to ECT was not statistically significant. 
 
Fahy et al. (1963) – 9/24.  The second U.K. study was not a SECT study at all. It compared 
ECT to sleep induced by general anaesthetic, but: ‘No attempt was made to suggest to these 
patients that they were receiving ECT. As far as they knew, the sleep injection was a 
complete treatment in its own right’ (p. 311). Despite this and numerous other flaws (see 
Table 3) this study was, again, included in the Janicak and Pagnin meta-analyses. Neither 
mentioned the absence of a SECT group when including the study in their effect-size 
calculations. The difference, in terms of percentage ‘recovered or minimal symptoms only’ 
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between ECT (35%) and SECT (12%), assessed by a doctor was not statistically significant. 
Percentages were not reported for the staff’s ratings (thereby meeting the Cochrane ‘risk of 
bias’ criterion of ‘selective reporting’), but graphs show that the difference was even smaller 
than for the doctors. Both meta-analyses use the larger of the two in their calculations. 
 
Wilson et al. (1963) – 12/24.  This small USA project involved 12 ECT patients and 12 
SECT patients, with half of each group on an antidepressant. The only meta-analysis to 
include this study (UK ECT Group, 2003) correctly reports only the data for the two groups 
of six not taking the antidepressant. On both the Hamilton (Hamilton, 1960) and the MMPI-
Depression (Schiele, Baker, & Hathaway, 1943) scales the ECT group showed significantly 
more improvement than the SECT group. The meta-analysis fails to report that one of the two 
raters before treatment, and one of the three at the end of treatment, knew which patients had 
received which treatment, so the study was un-blinded. The ratings were not statistically 
different from each other, and were based on ‘the same interview’ so it is quite possible that 
the blind raters were influenced by the non-blind rater. Multiple other failings are listed in 
Table 3, including the exclusion of people aged 60 or older, i.e. typical ECT patients. 
 
Freeman et al. (1978) – 13/24. The first of the second wave of studies (1978 - 1985) 
occurred in Scotland. The only meta-analysis to include it was the one by the UK ECT 
Group. Like Harris & Robin (1960), this study invalidated any evaluation of the efficacy of a 
full course of ECT treatment by giving ECT to the SECT group before the end of the study 
(after just two ECTs). These two studies evaluate speed of response early in treatment but not 
efficacy of the whole treatment. After the two ECTs three clinician-rated scales recorded 
significant differences between the two groups, but there was no difference when the patients 
rated their own depression. The researchers (Freeman et al., 1978, p. 738) explained: 
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The ideal design for such a trial would have been to have compared a full course of S.E.C.T. with 
a full course of real E.C.T. . . .  We felt it ethically unjustified to withhold for a complete course a 
treatment generally regarded to be effective and to submit patients to perhaps unnecessary general 
anaesthesia. The method presented here was therefore a compromise.  
 
Four of the 18 ECT patients, but none of the SECT patients, withdrew because they were 
‘non-responders’, but they were not included when calculating means.  
This was the only study to report whether participants had been tried on antidepressants 
prior to the study; 22 (54%) had not. 
 
Lambourn & Gill (1978) – 17/24.  This study was one of the two highest scorers for Quality. 
It provided individual Hamilton scores, plus doctors’ ratings, for all 32 participants, who had 
been randomised to the ECT and SECT groups, matching for age and gender. The blindness 
of the raters was assessed and confirmed.  The participants were representative of the age and 
gender mix of ECT recipients. Most (66%), however, had had ECT before, thereby increasing 
the probability of un-blinding for those patients.  
The study differed from most studies by using unilateral, rather than bilateral, electrode 
placement. It also differed by studying people diagnosed with ‘depressive psychosis’, 
although they were severely depressed. The following can be calculated from the individual 
scores. There was no significant difference in the mean reduction on the Hamilton scale 
(using the old scoring system in which the ratings of two raters are added together) between 
the ECT (26.2) and SECT (22.8) groups (t (30) = .50, p = .62). On the doctors’ ratings 37.5% 
of both groups were rated 3 on an undefined 0-3 scale, and 69% of the ECT group and 62.5% 
of the SECT group were rated 2 or 3, a nonsignificant difference (X2 = 0.14, p = .71). Using 
all four ratings (0-3) also produces a nonsignificant difference (X2 = 1.25, p = .74). 
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This study was included in all meta-analyses except the recent one (Mutz et al., 2019). 
Table 4 shows that four different effect sizes were calculated by the four meta-analyses, 
ranging from 0.17 (UK ECT Group) to 0 (Pagnin et al.; Odds Ratio = 1.0). None of them 
reach the threshold of even a ‘small’ effect size (0.2; Hamilton, 1960). 
 
Johnstone et al. (1980) – 17/24. The famous Northwick Park study was one of the largest, 
and is the other of the two highest scorers on the Quality scale. Neither the ratings by the 
nurses nor the self-ratings by the patients produced significant differences between the 31 
ECT patients and the 31 SECT patients. There was, however, a significant difference on 
change in Hamilton scores rated by a psychiatrist. The reporting of the findings is 
problematic. There were no data or SDs reported for the two outcomes that found no 
significant difference between ECT and SECT (by nurses and patients), making them harder 
to include in meta-analyses. There was just one rather basic graph, for the psychiatrist’s 
Hamilton ratings.  
Furthermore, despite including three sub-types of depression Johnstone et al. failed to 
report separate findings for them. Re-analysis by Buchan et al. (1992) suggests that the 
difference between ECT and SECT on the Hamilton is only significant for the patients who 
were deluded as well as depressed (although it is hard to be sure because Buchan and 
colleagues merge the data for the sub groups with data from the Brandon et al. study).  
Only one meta-analysis (UK ECT Group) includes this relatively rigorous, but poorly 
reported, study.  
 
West (1981) – 13/24.  This small study was reported in just two pages, by a sole author. The 
11 who received ECT were reported to have improved significantly more than the 11 
receiving SECT, on separate ratings by psychiatrists, nurses and patients. West concluded his 
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findings were ‘very strong evidence’ and that ECT is ‘an excellent treatment of severe 
depression’. The differences were much larger than in any other studies. Unlike the other 
studies, there was virtually no change in the SECT group.  
The nurses’ scale raises further concerns about the integrity of the study. The scale was 
described as a nine point scale from ‘very much worse’ to ‘very much better’, but scores were 
reported at baseline, before any treatment had taken place. One cannot be ‘worse’ or ‘better’ 
before a study begins.  
One patient from each group was withdrawn in week one due to ‘lack of improvement’. If 
both had been scored as 0 improvement, rather than excluded, this would, in such small 
groups, have slightly reduced the difference in mean improvement scores between the two 
groups. For example, the difference between the ECT and SECT groups in the mean amount 
of change in the psychiatrist’s ratings would have fallen from 41.1 (48.4 vs 7.3) to 37.7 (44.4 
vs 6.7). An additional ECT patient was withdrawn in week one because s/he ‘could not 
complete the Beck Depression Inventory’. This person was withdrawn after baseline 
assessments so they must have become unable to respond to written questions on a 0-3 scale 
after one or two ECTs. So while it appeared that 11 out of 11 ECT patients improved 
significantly, the true proportion was 11 out of 13. 
Despite the assertion that ‘These findings confirm the value of electric convulsion therapy 
in severe depressive illness’, the two groups had average baseline Beck scores of only 24 and 
27, which are within the ‘moderate’ range (20-28) (Beck, Ward, Mendelson, Mock, & 
Erbaugh, 1961). The baseline scores for the psychiatrists’ ratings, on a scale with 100 
representing ‘most severe depressive illness’, were only 68 and 71. 
Brandon et al. (1984) (reviewed next), commenting on the West study, raise concerns 
about ‘The sample size, the unusually unequivocal result, problems of selection, and doubts 
about the extent to which blindness was achieved’ (p. 23). West did not tell us how blindness 
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was achieved by either ‘the psychiatrist in charge’ or by the ‘nurses’. We were not told how 
many nurses were raters, or anything about their role in treatment. We were not told how 
many patients had enhanced probability of knowing whether they had received ECT in the 
study because they had had it before. The ‘blindness’ of the raters was not assessed. 
Despite all these failings three meta-analyses include this study (using the data that 
ignored the two withdrawals), and use its aberrantly large pro-ECT findings in their 
calculations (Janicak et al., 1985; Pagnin et al., 2004; UK ECT Group, 2003).   
  
Brandon et al. (1984) – 16/24.  The largest of the 11 studies (77 patients) took place in 
Leicester, England. It was a relatively high quality study. The samples were typical of ECT 
recipients in terms of depression severity, gender and age. The blinding process was 
described and tested. Apart from failing to report means and SDs (provided later by Buchan 
et al.), other failings included the fact that 60% had had ECT before (thereby reducing the 
probability of genuinely blind ratings by the patients) and that the patients’ self-report scores 
were not reported. No explanation is given for this selective reporting.  
On both the Hamilton and a psychiatrist’s rating scale the 43 in the ECT group improved 
significantly more than the 34 in the SECT group. Analysis by Buchan and colleagues, of the 
Brandon et al. (1984) and Johnstone et al. (1980) studies combined, however, found that the 
differences in Hamilton scores were only significant for patients who were ‘deluded’ or 
‘retarded’ (slowed thoughts), which was less than half of the participants in the two studies 
(45%) (Buchan et al., 1992, p. 357).  None of the three meta-analyses that include the 
Leicester study (or the one that includes Johnstone’s Northwick Park study) acknowledge 




Gregory et al. (1985) – 10/24.  The last ever ECT vs SECT study took place 34 years ago. 
The ‘Nottingham ECT Study’ actually had three groups. The ECT participants were divided 
into two groups by electrode placement (unilateral or bilateral). It is almost impossible to 
make sense of the findings. ‘Of the 69 patients entering the study, 25 received fewer than six 
study treatments; these were classed as withdrawers’ (p. 521). Of these 25 withdrawers 14 
were because of ‘failure to improve’ and five because they ‘were better’. So 19 of the 69 
participants (27%) in a study designed to determine who got better were withdrawn because 
they did, or did not, get better. (Three of the withdrawers in the ECT group, but none in the 
SECT group, withdrew consent after the study started). To further confuse matters Table 1 in 
Gregory et al. reports the mean scores of 60 people with ‘complete data available’ although 
there were only 44 participants remaining after the 25 were withdrawn. A graph portraying 
changes on the Montgomery-Asberg depression scale (MADRAS) (Montgomery & Asberg, 
1979) seems to have numbers for each of the three groups closer to those expected when 
subtracting the withdrawers. Their Table reports ‘percentage changes’ that are more than 
twice as large for the SECT group as for either of the two ECT groups, on both the Hamilton 
and MADRAS. Finally, a ‘global assessment of change in depression’ was made, but not 
reported (thereby meeting the Cochrane criterion of ‘selective reporting’). 
A Cochrane review on ECT for ‘the depressed elderly’ set out  to calculate an effect size 
for the 35 participants over the age of 60 in this study but found that insufficient data had 
been provided to make that possible (van der Wurff et al., 2003).  
The only meta-analyses that includes this study (UK ECT Group) fails to acknowledge 
any of these problems and unquestioningly included the strong finding in favour of ECT in 
their calculations of effect sizes.  
 
Follow Up Findings 
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Seven of the 11 studies provided follow-up data, but we shall see that only three produced 
meaningful data for comparing ECT and SECT. An eighth study had stated ‘We hope to 
report longer term effects in a later article’ (Fahy et al., p. 310), but they didn’t.  
 
Ulett et al.  Six months after the end of treatment a comparison was made using patients who 
had been discharged and not received ECT after the end of the study period. Four of the 11 
who had had ECT (36%) had relapsed, compared to none of the four in the SECT control 
group. The majority of patients in this study, however, did not have a depression diagnosis so 
this finding is irrelevant to the current review. 
. 
Brandon et al. and Gregory et al.  Although neither Brandon et al. (2 and 6 months follow-
up) nor Gregory et al. (1 and 6 months) found significant differences between ECT and SECT 
at follow up, both studies invalidated any evaluation of long-term benefits by giving ECT to 
most of the SECT group during follow-up.  Brandon et al. gave ECT to 20 of its 34 SECT 
participants, and to 17 of the 42 in the real ECT group, during follow up. Gregory et al. gave 
an average of 4.1 ECTs to their SECT group and 1.5 to their ECT group during follow-up.  
 
West.  West reported psychiatrists’ scores on a 0-100 scale (but not the nurses’ or patients’ 
scores), five days after the last treatment. The difference in the size of change from baseline 
was an enormous 53.6 points (52.1 vs -1.5). If such data can be believed they would produce 
a rather incredible effect size (Cohen’s d) of 3.22. We have already noted the serious 
methodological failings of, and ominous questions about, this study.  
West then followed up for a further three weeks, but like Brandon et al. and Gregory et al. 
gave ECT to most of the SECT group (ten of the eleven).  
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Further suspicion about this study comes from the fact that at the end of the first part of 
the study the mean psychiatrists’ score for the 11 SECT patients was 63.4, but the ‘base’ 
mean score for the follow-up study, for the ten remaining SECT patients, was reported to 
have jumped to 73.4. This is not mathematically possible by excluding just one of 11 people.  
 
Brill et al.  This early USA study did not assess outcomes till a month after treatment ended. 
As we have seen, 16 of the 21 men in the ECT group (76%) and 4 of the 9 SECT patients 
(44%) met the researchers’ criterion for recovery. The difference is not statistically 
significant (X2 = 2.86, p = .09). The effect size (d) is 0.297 (95% CI -0.44 – 1.04). This study 
had extensive methodological flaws, scoring only 9 on the Quality scale. As noted earlier, it 
involved 97 men with an average age of 35, so was totally unrepresentative of the modal ECT 
recipient – a woman in her 60s.   None of the outcome measures explicitly assessed 
depression. ‘Nearly half’ of the participants had had ECT before. 
 
Lambourn & Gill.  Lambourn and Gill also followed up participants for a month. Because 
they reported detailed data for individual patients it is possible to calculate mean outcomes 
for the seven ECT patients and eight SECT patients who did not have ECT during the follow-
up month.  The researchers used a 67% or greater improvement (from baseline) on Hamilton 
scores as an indicator of improvement. This was achieved, at one month follow-up, by four of 
the seven ECT patients (57%) and five of the eight SECT patients (62%). The mean 
reductions in Hamilton scores were 30.57 (sd  = 18.61) for the ECT group and 35.75 (sd = 
17.65) for the SECT group, producing a difference of 5.18 and an SD for the whole sample of 
18.10, which produces a ‘small’ effect size (d) of 0.299, in favour of SECT.  




Johnstone et al.  Johnstone et al. assessed at one month and six months post-treatment, on 
three scales. There had been a significantly greater drop in Hamilton scores at the end of 
treatment for the ECT group, but: 
The advantage of real over simulated ECT was not retained and at the one-month and six-
month follow-ups the Hamilton scores of the two groups were almost the same. The Leeds 
self ratings showed similar trends but these were never significant, and this was also true of 
the ratings by nurses” (p. 1318).  
 
So none of the three sets of raters found a significant difference between ECT and SECT at 
one or six months after the end of treatment. Johnstone et al. reported no specific follow-up 
data, just graphs.  Buchan et al. (1992), however, provided Johnstone et al.’s six months 
mean improvement scores on the Hamilton (but not the nurses’ or patients’ ratings). The 
mean reductions were 36.33 for the ECT group and 35.30 for the SECT group. Calculating an 
effect size for this small difference (1.03 points) is problematic, as we do not know the SDs. 
The SEs for the data at the end of treatment (3.0 for ECT and 2.7 for SECT) translate into 
SDs of 16.70 and 15.03 respectively (SD = SE x √N). If we use those as estimates of the SDs 
after six months, the 1.03 difference between the amount of change in the two groups 
translates into an effect size of 0.065. This does not approach the 0.2 level for a ‘small’ effect 
size (Cohen, 1988). 
 
Brandon et al. concluded (p. 23): 
The well designed and carefully-controlled clinical trial . . .  [Johnstone et al.] showed that 
electroconvulsive therapy had only a small effect in depression at the end of the trial period and 
there was no difference in the condition of patients given real and simulated treatment at one and 




Johnstone and colleagues, themselves, emphasised this point (p. 1319): 
The most striking finding is that the differences which were present at the end of the course of 
eight treatments had disappeared one month later and were undetectable also at six months  
 
Conclusion re. long term efficacy.  A conservative conclusion from the four studies that 
provided some relevant data would be that there is no evidence that ECT has any lasting 
benefits beyond five days. Given all the problems with the West study it seems reasonable to 
exclude it from considerations and conclude that there is no robust evidence of ECT having 
any benefit at all beyond the last day of treatment.   
If we consider only the three studies with data for at least one month we are left with one 
small effect size, .297, in favour of ECT (Brill et al.), one study with a trivial effect size, .065,  
in favour of ECT (Johnstone et al.) and one with a small effect size, .299, in favour of SECT 
(Lambourn & Gill).  If we exclude the Brill study because of its multiple methodological 
flaws (not least its failed blinding process, and its being based on a very atypical sample of 
middle-aged men) we are left with Lambourn & Gill and Johnstone et al., two of the three 
highest Quality studies. Neither of these two studies, one with unilateral electrode placements 
and one with bilateral, provide any evidence of any long term benefits of ECT compared to 
SECT.  
- - Table 4 about here - - 
The Five Meta-Analyses 
The first meta-analysis (Janicak et al.) was published in 1985, possibly too early to consider 
the last study (Gregory et al.). Three meta-analyses were published nearly 20 years later, in 
2003 or 2004. The last was published in 2019.  All five concluded that ECT is more effective 
than placebo.  
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The five meta-analyses include, between them, the eleven ECT vs SECT studies described 
above. Table 4 shows the marked variation in the number of studies included in the meta-
analyses, from one (Mutz et al., 2019) to seven (Pagnin et al., 2003). No study was included 
in all five meta-analyses. Most (eight) were included in just one or two meta-analyses.  
 
Janicak et al. (1985). 
Inclusion criteria.  The first meta-analysis, by Janicak and colleagues, includes six studies 
(Table 4). The ‘most important’ inclusion criterion is the ability ‘to determine each patient’s 
response to treatment’ (p. 298), and ‘the assessment of each patient’s response was 
determined by the author’s designation of the patient as a responder or nonresponder’ (p. 
298). Five of the six included studies meet the criterion (see Table 3). One study does not but 
is included anyway; the one with the strongest outcome in favour of ECT (West, 1981). 
Although West recorded that it was considered ‘therapeutically desirable’ (without stating by 
whom or by what criteria) for ten of the 11 SECT patients to receive ECT in the second part 
of his study, he neither reported any scores or categorisations for individual patients nor 
designated participants as ‘responders’. A second criterion is ‘systematic method for 
diagnosing the patient as depressed’. This is not the case for three of the six (Table 3). A third 
criterion is that depression be ‘severe’. Only two of the six studies met this criterion (Harris 
& Robin; Lambourn & Gill). One stated ‘Severe depressions with high suicidal risk were not 
included’ (Fahy et al., p. 310). 
Quality control.  Janicak et al. (1985) make no attempt to evaluate the methodological 
rigour of the six studies. They are either unaware of, or actively ignore, the 72 specific 
instances of methodological failings across the six studies (see Table 3). The six included 
studies had a slightly lower mean Quality score (11.17) than the five excluded studies 
(13.60), but the difference is not significant (t (9) = 1.30, p = .26). 
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Short-term findings.  Efficacy was calculated ‘by taking the difference in percentage 
efficacy between real ECT and SECT and averaging across all studies’. The reviewers report 
an ‘overwhelming statistical superiority of ECT over SECT’ (p. 301).  
The totals they report from their six studies are 72% for ECT and 40% for SECT; hence 
the assertion that ECT is ‘32% more effective’ (p. 298). This is an incorrect calculation of the 
two percentages from their own Table (p. 299). The numbers are, for ECT 73/109, which is 
67% not 72%: and, for SECT, 33/96, which is 34% not 40%. These errors do not significantly 
alter the overall difference between the two conditions, but do indicate carelessness. 
More importantly, the reported percentages of two of the six studies are incorrect. In their 
report of the Ulett et al. (1956) study, Janicak et al. wrongly include the data of patients 
subjected to photoshock. Without these patients the correct figures are ECT 7/21 (33%) vs 
SECT 5/21 (24%), a 9% difference, compared to a 30% difference (65% vs 35%) when the 
photoshock participants are included.  Secondly, Brill et al. (1959) had reported (p. 630; 
Table 3) that the percentages  meeting their criterion of showing improvement on two of their 
three measures as 76% ‘shock’ vs 44% ‘non-shock’ (16/21 vs 4/9). Janicak, however, report 
67% vs 25% (p. 299; Table 1), thereby inflating the difference between real and SECT from 
32% to 42%. The percentages using the correct numbers for the five studies that did report 
percentages of ‘responders’ (i.e. excluding West et al. – see above) are: ECT 45/79 (57%) vs 
SECT 25/67 (37%), a difference of 20%, rather than 32%. This is statistically significant (X2 
= 5.61; p < .05), but not as strongly as Janicak’s claim of X2  = 21.54 (p < .0001). 
Four of their six studies (Ulett, et al., 1956; Brill et al., 1959; Harris & Robin, 1960; Fahy 
et al., 1963) have the most methodological flaws of the 11 studies (see Table 3), all four 
having a Quality score of ten or less out of 24 (see Table 3). 
Follow up findings.  Janicak et al. acknowledge that ‘questions such as those raised by’ 




Kho et al. (2003). 
Inclusion criteria.  Eighteen years later Kho and colleagues, publishing their meta-
analysis in the Journal of ECT. It was based on just two studies. They excluded all pre-1978 
papers, because of their diagnostic ambiguities (p. 140) and because they wanted to 
determine ‘whether the superior efficacy of ECT is still found using more recently published 
studies’ (p. 140). This assumption, that ECT had already been shown to have ‘superior 
efficacy’, might be considered a sign of bias on the part of the authors.  
Kho et al. set out to include only studies reporting means and standard deviations 
generated with depression rating scores such as the Hamilton (1960). They exclude two 
studies which meet this criterion (Johnstone et al; West), without explanation, and rely 
instead on just two studies (Brandon et al.; Lambourn & Gill).  
Quality control.  Kho et al. assess the quality of the studies on a 0-5 scale based on 
randomization, double blindness and description of withdrawals. Eight of the sixteen various 
types of studies included in their broader meta-analyses scored 0 out of 5. They fail, however, 
to report the scores of individual studies.   
This is the only meta-analysis where our 24-point Quality scale produces a significantly 
higher mean score for the included studies (16.50) than the excluded studies (11.33); (t (9) = 
2.59, p = .029).  
Short-term findings.  The two studies, involving 59 ECT patients and 50 SECT patients, 
produced four effect sizes. The reviewers calculate a pooled effect size (delta) of 0.95 (95% 
interval - 0.35-1.54). The reported effect sizes for the three sub-types of depression in the 
Brandon et al. study range from 1.38 to 1.99, all far higher than the 0.77 calculated by Pagnin 
for the three subtypes combined. Kho et al. acknowledge that ‘because the three ESEs from 
the Brandon study may be correlated, the results from the comparison between ECT and SET 
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may be exaggerated’ (p. 145). So three of the four effect sizes may have been ‘exaggerated’ 
and the fourth (Lambourn and Gill) was calculated as 0.09. 
Kho et al. fail to mention any of the problems of the two studies listed in Table 3, 
including the fact that in the Brandon et al study 60% had had ECT before (thereby 
significantly compromising the  blindness of the ratings by the patients) and that the patients’ 
self-report scores scale were not reported.  
Follow-up findings. The issue of efficacy beyond the end of treatment was not mentioned. 
 
UK ECT Group (2003). In the same year, 12 reviewers, led by Oxford University 
psychiatrists, published a meta-analysis funded by (but independent from) the UK 
Department of Health, and published in the Lancet. It is the only one of the four meta-
analyses published at the time that was considered to be a ‘good-quality systematic review of 
randomised evidence’ by a subsequent 170 page UK report for the NHS (Greenhalgh et al., 
2005).  
Inclusion criteria.  The ‘primary outcome’ is ‘a continuous depressive symptoms scale’ 
but ‘dichotomous data are merged to produce estimates of odds ratios’ and the two are 
combined using ‘numerical simulation techniques based on Gibbs sampling’ (p. 800). 
Six of the 11 studies are included (see Table 4). Freeman et al. and Harris & Robin are 
included despite having invalidated their findings by giving ECT to the SECT group. There is 
no explanation for excluding four of the other five (although Table 3 shows there are good 
reasons to do so). Brandon et al. is excluded ‘because 43 patients had non-depressive 
diagnoses’ (p. 806). This is incorrect. The 43 had been omitted from the study.  
Quality control.  Greenhalgh et al. (2005, p. 15) note that ‘Little information was provided 
in the review [UK ECT Group] regarding the characteristics of participants in terms of the 
nature and severity of their condition, medication history and previous use of ECT’. Quality 
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is, however, evaluated, using four criteria: ‘reporting of allocation concealment, masking, 
loss to follow up and length of follow up’ (p.799). The UK ECT Group do comment that 
‘The quality of reporting of the trials was poor’ (p. 801), but fail to report the performance of 
individual studies. The reviewers acknowledge the small sample sizes and the absence of data 
on patients who are ‘most likely to receive it – e.g. older patients…’ (p. 806). They are, 
however, unaware of, or actively ignore, the 47 other specific instances of methodological 
failings across their six studies (see Table 3).  
The quality of the six included studies does not differ significantly from that of the five 
excluded studies (13.67 vs. 10.60) (t (9) = 1.74, p = .12). 
Short-term findings.  Unlike the other meta-analyses, which all presupposed that ECT is 
effective, these reviewers started by acknowledging that views vary, from ‘it is probably 
ineffective but certainly causes brain damage …. through to those who think it is the most 
effective treatment available in psychiatry and is completely safe’ (p. 799).   
This is the only meta-analysis to include the Johnstone et al. study. Only the statistically 
significant outcome (Hamilton ratings by a single psychiatrist) is included. The non-
significant findings, from the nurses’ and patients’ ratings, are ignored, without explanation.  
This is also the only meta-analysis to include Freeman et al. It doesn’t mention that ECT 
was given to SECT patients after a week, or that 20% of ECT patients withdrew unimproved.  
The two studies with the largest effect sizes (Gregory et al.; West et al.) both have 
multiple methodological shortcomings (see above and Tables 2 and 3).  
Ignoring all these problems the reviewers go on to combine the categorical and continuous 
outcome data to produce a pooled effect size of 0.91 in favour of ECT. The other four meta-
analyses reached a generalised, unqualified conclusion that ECT ‘is effective’. Although the 
the UK ECT Group also concluded that ‘In the short-term (ie at the end of treatment), ECT is 
an effective treatment for adult patients with depression’ (p. 806), they added: 
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There is limited randomised evidence on the efficacy of ECT in the specific subgroups of patients 
who are presently most likely to receive it – eg, older patients or those with treatment-resistant 
illnesses – or in subgroups of patients in whom ECT is thought to be especially effective. (p. 806) 
 
Multiple emails were sent by JR to the lead author, Professor John Geddes, and other 
members of the UK ECT Review Group, seeking clarification about all the concerns raised 
above. Despite polite acknowledgements of the emails none of the questions were answered. 
 
Follow-up findings.  This was the only meta-analysis to investigate longer term efficacy. 
Only one study is identified (Johnstone et al.) and ‘a non-significant two-point difference in 
final HDRS [Hamilton] was noted in favour of the simulated group’ (p. 801). This is 
potentially misleading, in favour of SECT. Although the SECT group did end up two points 
lower, the ECT group had started off more depressed and had actually changed 1.03 points 




Pagnin et al. (2004). 
Inclusion criteria. The fourth meta-analysis was published in the Journal of ECT. It 
includes the largest number of studies, seven, and the largest number of people, 245. Like 
Janicak et al., the reviewers include only studies from which they could ‘determine each 
patient’s response to treatment, using author’s own criterion of response or no response. ’ (p. 
13), correctly excluding Freeman et al., Johnstone et al., and Gregory et al. on that basis, but, 
like Janicak et al. and the UK ECT Group, dubiously including West. 
Quality control.  Pagnin et al. make no attempt to rate studies in terms of methodological 
rigour. The difference between the mean Quality scores of the included studies (11.86) was 
24 
 
not significantly different from that of the four excluded studies (13.00), (t (9) = .55, p = .60). 
The reviewers acknowledged problems with ‘diagnostic heterogeneity,’ randomization, and 
maintaining blindness, but without naming any specific studies. They were unaware of, or 
actively ignored, the 74 other specific instances of methodological failings across the seven 
studies (see Table 3).   
Short-term findings.  Despite only two of the seven studies (Brandon et al., 1984; West, 
1981) producing a significant difference, the studies do, when combined, find a significantly 
greater mean effect size for ECT than for SECT at end of treatment (X2 = 6.87, p = .009). 
Four of the seven included studies had the four lowest Quality scores of the 11 (see Table 3) 
(Brill et al., Fahy et al., Harris & Robin; Ulett et al.) and were excluded by three of the other 
meta-analyses (Kho et al.; UK ECT Group; Mutz et al.) (see Table 3). It is also unclear how 
the effect sizes were calculated. For example Pagnin et al. report an effect size (D) of 1.341 
for the Brill et al. study (Table 3, p. 15). Yet the 16/21 vs 4/9 improved ratios produce an 
effect size (D) of 0.297 (95% CI -0.44 – 1.04) (using 
www.campbellcollaboration.org/escalc/html/EffectSizeCalculator-SMD9.php) (see Table 4). 
The reviewers acknowledge that any advantage of ECT over SECT is only ‘specifically 
among patients with delusions and/or retardation [slowness of thought]’ (p. 19).  
Follow-up findings. The absence of any evidence of efficacy beyond the end of treatment 
is, again, not mentioned. 
 
Mutz et al. (2019). 
Inclusion criteria. The most recent meta-analysis, from the Institute of Psychiatry in 
London, appeared 15 years later, in the British Medical Journal (Mutz et al., 2019). It differs 
from previous meta-analyses in being a network meta-analysis, making pair-wise 
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comparisons, between four types of ECT and 14 types of brain stimulation, and, when 
possible, comparing these to sham placebo treatments.  
Inclusion criteria required use of the Hamilton or Montgomery scales and a manual-based 
diagnosis of ‘major depressive disorder’ or ‘bipolar depression’. Outcomes were efficacy and 
discontinuation/acceptability. Only two of the eleven studies were included (Brandon et al., 
Gregory et al.). Although not immediately apparent from the article, only one study (Brandon 
et al.) actually contributed to the analysis regarding efficacy. A personal communication 
(Mutz, 24.6.2019) responding to multiple questions from JR, explained: ‘The Gregory et al. 
(1985) study only contributed to the summary odds ratio for all-cause discontinuation as the 
authors did not report sufficient data in their paper to compute efficacy estimates’. 
Seven of the other nine studies are not mentioned at all, even in the 13 page ‘Full Texts 
Excluded’ section of the Supplementary Material (pp. 32-44). The final two studies (Freeman 
et al., 1978; Johnstone et al., 1980), both published in the Lancet, are categorised as ‘Cannot 
be obtained’ (Supplementary Material, p. 39). The personal communication did not answer 
the question ‘Does the Institute of Psychiatry not have access to papers published in the 
Lancet?’ but did state that if they had managed to obtain these two papers (which JR had by 
now sent to them) neither would have met their inclusion criteria. The personal 
communication said the same of the seven studies which their paper failed to mention at all, 
but which they had also subsequently been sent by JR. For example, Mutz et al. were the only 
meta-analysis not to include the Lambourn and Gill study.  The personal communication 
explained: ‘This trial was excluded as it did not meet our inclusion criteria of RDC, DSM or 
ICD diagnosis of major depressive disorder or bipolar depression’. 
So even after being sent all the studies which their search had missed, or they could not 
obtain, the Institute of Psychiatry reviewers conclude that after 80 years only one ECT- 




Quality control.  The meta-analysis by Mutz et al. (2019) is the only one to report any sort 
of quality ratings for specific studies. Using Cochrane criteria they assess the only study they 
consider robust, in terms of their inclusion criteria, as having a ‘high risk’ of bias, the worst 
Cochrane category.  
Short-term findings.  Mutz et al. claim that their ‘network meta-analysis’ produce odds 
ratios, relative to sham treatment, significantly in favour of ECT for ‘Bitemporal ECT’ 
(bilateral) and ‘High-dose Unilateral ECT’, but that the odds ratios for ‘Bifrontal ECT’ and 
‘Low to Moderate-Dose Unilateral ECT’ are not significant. But the single ECT-SECT study 
they included only studied bilateral ECT, so conclusions about whether the other three 
electrode placements were superior to SECT were based on no ECT-SECT data at all. The 
personal communication explained:  
In the absence of head-to-head clinical trials, network meta-analysis allows us to estimate such 
treatment effects using data available from other treatment comparisons that share comparison 
treatments. For example, if we have data on treatment A vs treatment B and data on treatment A vs 
treatment C, we can estimate the effect of treatment B vs C. Please note that this is a somewhat 
simplified explanation. 
 
In response to being asked why their review methodology led to an odds ratio for bilateral 
ECT far higher than the odds ratio calculated by the Pagnin et al. meta-analysis for the 
Brandon study, the reviewers replied: ‘The network meta-analytic ORs are not directly 
comparable to the individual study OR presented in the Pagnin et al. (2004) meta-analysis.’ 
This is very true. The OR calculated by Pagnin et al., based directly and solely on the ECT-
SECT data of the Brandon study was 2.2. The OR calculated by Mutz et al., based on the 
Brandon data plus a lot of studies which do not compare bilateral ECT and SECT, is an 
enormous 8.9. Furthermore, their very large 7.3 OR for High-dose Unilateral ECT, is based 
entirely on studies that do not compare ECT and SECT.   
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We have already noted that the only ECT-SECT efficacy study that met their inclusion 
criteria was rated, by the reviewers themselves, as ‘high risk’ of bias (Mutz et al., 2019, 
Supplementary Material, pp. 49, 50). They add: 
‘Overall risk of bias was deemed high in 19 trials (17%). In a sensitivity analysis excluding these 
trials, we found that … treatment effects of ECT protocols and magnetic seizure therapy versus 
sham therapy could not be estimated. (Mutz et al., 2019, p 10). 
 
Nevertheless, they ignore their own statement, and proceed to estimate and report them, 
unqualified, in the Abstract: 
‘10 out of 18 treatment strategies were associated with higher response compared with sham 
therapy: bitemporal ECT (summary odds ratio 8.91, 95% confidence interval 2.57 to 30.91), high 
dose right unilateral ECT (7.27, 1.90 to 27.78) …... (Mutz et al., 2019, p.1)’ 
 
Follow-up findings.  The reviewers make no attempt to review the literature regarding 
longer-term effects of ECT. 
 
DISCUSSION 
The Quality of the Eleven Studies 
Table 3 shows that the 11 studies produced Quality scores, on our 24-point scale, ranging 
from 9 to 17, with a mean score of 12.27 (sd = 3.20). Only three produced scores above 13.  
The empirical support for using ECT prior to 1978 had consisted of just five ECT vs 
SECT studies, on a total of 67 ECT patients and 57 SECT controls, with a mean Quality 
score of 9.80 out of 24. Four of the five had found no difference between ECT and SECT. 
The one finding a significant difference (Wilson et al., 1963) involved just four ECT patients.  
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The quality of this body of literature as a whole is unimpressive, and is clearly unable to 
determine whether ECT is more, or less, effective than SECT in reducing depression. Table 3 
shows, for example, that five of the 11 studies (including three of the second wave) failed to 
describe their randomisation process. Five (including two later studies) reported no attempt to 
test their blinding process. Of the six that did so, five assessed the blindness of the raters but 
not that of the patients; mostly by asking raters to guess whether patients had received ECT 
or SECT and finding no more agreement than that expected by chance (Brandon et al.; 
Freeman et al.; Johnstone et al.; Lambourn & Gill), and in one instance by just reporting that 
it was ‘easy’ for the observers to infer which treatment had been allocated (Fahy et al., p. 
1963). The sixth study (Brill et al.) tested the patients but not the raters, reporting that ‘some 
patients in the nonshock group believed that they were receiving some new variation of 
ECT’. So none of the studies tested the blinding process for both the raters and the patients.  
The second reason that none of the studies can reasonably claim to be double-blind is that 
none of them excluded people who had previously had ECT, so some members of the SECT 
groups would probably know they had not had ECT because they would know that ECT is 
always followed by headaches and temporary confusion. None of the studies showed any 
awareness of this issue. Five of the 11 did not even report how many people had previously 
had ECT (see Table 3). Table 2 shoes that the other six reported percentages ranging from 
21% (Johnstone et al., 1980) to 66% (Lambourn & Gill, 1978), with a weighted mean of 
45.1% (the ‘nearly half’ reported by Brill et al. was interpreted to be 14/30; 47%). So about 
half the patients in the SECT groups would probably have guessed that they had not had 
ECT. Therefore, none of the studies could genuinely be described as double-blind.  
Two thirds of ECT recipients are women and the average age is between 60 and 65 (Read 
et al., 2010; 2018); so the modal ECT person is a woman in her early sixties. Tables 2 and 3 
show, however, that only three studies met the criterion of being broadly representative of the 
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demographics of ECT recipients by using samples that were mostly female and had an 
average age of at least 50. None of the studies showed any interest in age or gender. None 
analysed their findings by age or gender. None even reported ethnicity.  
ECT is supposed to be given to severely depressed patients. Current guidance from the 
UK’s National Institute for Health and Care Excellence states: ‘Consider ECT for acute 
treatment of severe depression that is life‑threatening and when a rapid response is required, 
or when other treatments have failed. Do not use ECT routinely for people with moderate 
depression…’ (NICE, 2009). Five studies, however, failed to demonstrated that their 
participants were severely depressed; three did not provide enough information to know, and 
two clearly had only (Fahy et al., 1963) or mostly (West, 1981) moderately depressed 
participants. One used participants (62%) without a depression diagnosis at all (Ulett et al.).  
Two of the 11 studies invalidated their findings by administering ECT to the SECT group 
part way through the studies (Freeman et al., 1978; Harris & Robin, 1960). Table 3 reports 
that only five studies reported means and standard deviations on a dimensional depression 
scale such as the Hamilton, which is valuable for calculating an effect size and thereby 
making a meaningful contribution to a meta-analysis. 
Only one of the studies reported whether other treatments (eg antidepressants or CBT) had 
been unsuccessfully tried prior to ECT, which would have rendered the study able to assess 
whether ECT is effective for people who are today recommended for ECT by NICE 
guidelines (see above). In the only study that did report, less than half (46%) had been tried 
on antidepressants prior to the study (Freeman et al., 1978).  
Only four studies included ratings by the patients themselves, and none assessed the 
impact of ECT, positive or negative, on their Quality of Life. 
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 The sample sizes were small, ranging (ECT and SECT groups combined) from eight 
(Harris & Robin, 1960) and ten (Wilson et al., 1963) to 77 (Brandon et al., 1984). The mean 
was 38.3; with 20.4 in the ECT groups, and 17.9 in the SECT groups. 
Five studies selectively reported their outcomes, failing to report one or more findings. 
 
The Quality of the Five Meta-Analyses 
All five of the meta-analyses claim that ECT is effective for depression but, as we have seen, 
they are all of a poor standard, not least because none of them pay sufficient attention to the 
quality of the papers on which they base this claim. The only meta-analysis conducted in the 
last 15 years, the one from the Institute of Psychiatry in London in 2019, is particularly 
problematic. Mutz et al. (2019) make strong claims about the efficacy of ECT on the basis of 
just one ECT-SECT study (Brandon et al.). They not only rated, themselves, that one study as 
having a ‘high risk’ of bias by Cochrane criteria but stated that exclusion of high risk studies 
made it impossible to estimate an odds ratio for ECT. Furthermore 67% of the other studies 
(not ECT-SECT) in their network analysis, used to indirectly calculate odds ratios were, 
themselves, either ‘unclear risk’ or ‘high risk’ (Mutz et al., 2019, p. 6). As was the case for 
the other four meta-analyses, major flaws have to be ignored to claim that ECT is more 
effective than SECT. 
Four of the five meta-analyses fail to report the quality of any of the studies they include, 
most of which are of a very poor standard. The exception is the recent Institute of Psychiatry 
meta-analysis, which, as we have seen, reports that the only study they include had an overall 
‘high risk’ of bias. It is worth noting that the study (Brandon et al.) that Mutz et al. assessed 
as having a ‘high risk’ of bias is the 3nd most rigorous study of the 11 studies according to our 
own Quality scale, suggesting that the other eight may be at least as equally problematic.  
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Given the overall low quality of the 11 studies it would be particularly important that only 
the best studies are included in meta-analyses. The authors’ apparent disinterest in the fact 
that none of the studies were actually double blind, in whether the participants were 
representative of who receives ECT in clinical practice, in whether ECT has any advantage 
over SECT beyond the end of treatment, and in the pervasive selective reporting, are all 
indicative of carelessness, bias, or both. 
 
Short-term Efficacy 
Contrary to the claims by the authors of all five meta-analyses, the small number of studies, 
the small samples and the plethora of fundamental methodological flaws of most of the 
studies, render it impossible to determine whether or not ECT is superior to SECT during the 
treatment period,. The only three studies scoring 16/24 or higher on the Quality scale 
produced the following outcomes:  
- Brandon et al. (16/24) - significant difference on psychiatrists’ ratings, but patients’ 
ratings not reported;  
- Johnstone et al. (17/24) - no difference on nurses’ ratings, no difference on patients’ 
ratings; significant difference on psychiatrists’ ratings (but for only two of three types 
of depression);  
- Lambourn & Gill (17/24) - no difference on Hamilton scores or on psychiatrists’ 
ratings.  
This amounts to one of seven sets of ratings being significant and one partially significant.  
While most of the 11 studies should never have been included in meta-analyses, it seems 
desirable to perform a meta-analysis on these three relatively high quality studies (keeping in 
mind that Mutz et al. evaluated the Brandon et al. study as ‘high risk’ of bias). However, this 
is impossible because al three are guilty of selective reporting.one (Johnstone et al.) failed to 
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provide any data for two of their findings (both were merely reported as nonsignificant) and 
another (Brandon et al.) failed to report anything at all about one of its two outcome measures 
(patients’ self-ratings). The only good quality study to fully report its short-term findings 




For the same reasons (but with even fewer studies) it is impossible to know whether or not 
ECT has any benefits, in terms of depression reduction, beyond the time of the last shock 
treatment. None of the three studies producing meaningful data found a significant difference. 
The best two studies found a near-zero effect size towards ECT of 0.065 (Johnstone) and a 
‘small’ (0.299) effect size in favour of SECT (Lambourn & Gill). So it could be tentatively 
concluded that there really is no benefit beyond the end of treatment. To do so, however, on 
the basis of just two or three small studies, would be wrong. The truth is, as is the case for the 
short term, we don’t know. 
 
Severely depressed / Suicidal / ‘Treatment non-responders’  
Even if one were to throw methodological caution to the wind, as the meta-analyses have 
done, and conclude that taken together there is some evidence that for the participants in the 
11 studies there is, in general, an ECT-SECT short-term difference, this could not be said to 
be true for the people who are supposed to receive ECT today – severely depressed, suicidal 
patients for whom other treatments have failed (N.I.C.E., 2009). Only six of the studies 
definitely included only or mostly severely depressed people. Two clearly did not. Although 
suicidal patients would probably have been included by chance in some studies, only two 
reported whether suicidal patients were actually included. The first actively excluded them 
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(Fahy et al.). In the second only four of 31 (13%) people starting the trial had previously tried 
to kill themselves; and three of these four were withdrawn from the study (Harris & Robin).   
We do not know, either, whether ECT is effective for people who have not responded to 
antidepressants or psychological therapies, the other major criterion for ECT use today, as we 
do not know how many, if any, such people were studied. 
 
Suicide Prevention 
Government and professional guidelines have claimed, for decades, that ECT prevents 
suicide. Suicidality is said to be a key indicator of suitability for ECT. None of the meta-
analyses report any findings that ECT is more effective than SECT at preventing suicide. 
There are none (Read & Arnold, 2017; Read & Bentall, 2010; Read et al., 2013). Although 
the Hamilton, MADRAS and Beck depression scales all include questions about suicidal 
intent, only one study reported these specific outcomes. Lambourn and Gill (1978) found 
mean reductions on the suicide item of the Hamilton scale of 3.38 points in the ECT group 
and 3.32 in the SECT group.   
The UK ECT Group states: ‘Although ECT is sometimes thought to be a life-saving 
treatment, there is no direct evidence that ECT prevents suicide’ (p. 806). The 170 page UK 
government report states: ‘The evidence did not allow any firm conclusions to be drawn 
regarding the … impact of ECT on all-cause mortality.’ (Greenhalgh et al., 2005, p. X). 
 
Quality of Life 
Quality of life measures can provide a more comprehensive and holistic assessment of our 
well-being than a depression scale; and one’s quality of life can influence one’s mood.  None 
of the studies attempted to determine whether ECT improves quality of life, a failing noted by 





Only five studies included (and only four reported) any measure completed by the patients 
themselves. We agree with Kingsley and Patel (2017) that patient-reported outcome measures 
should be included in clinical trials and meta-analyses of psychiatric conditions. In one of the 
four studies that did report the patients’ assessments of change, the psychiatrists reported a 
significant difference between ECT and SECT and the patients did not (Johnstone et al.).  In 
another study both the psychiatrists’ ratings produced a significant difference but only one of 
the two self-rated scales did so (Freeman et al.).  
 
Gender 
Women are twice as likely to receive ECT as men (Leiknes et al., 2012; Read et al., 2013; 
2018). Yet none of the 11 studies or meta-analyses reported whether ECT was more or less 
effective for this group. Seven of the eight mixed gender studies failed to report data by 
gender. The two all-female studies produced one positive (Wilson et al.) and one negative 
finding (Harris & Robin) - both with tiny samples.  
The only study to report data for individuals by gender (Lambourn & Gill) allows us to 
calculate that the nine women who received ECT had a mean reduction on the Hamilton of 
30.0 points, while the nine in the SECT group had a mean reduction of 18.6, a difference of 
11.4 in favour of ECT. The men, however, had mean reductions of 21.4 points with ECT and 
27.4 points with SECT, a difference of 6.0 points in favour of SECT. This suggests that ECT 
may be initially effective for women, but not for men. However, at one month follow up 
(excluding those who received ECT after the end of treatment) the four women in the SECT 
group had a mean improvement of 4.0 points greater than the four women in the ECT group, 
while the four men in the SECT group had a mean improvement of 9.7 points greater than the 
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three men in the ECT group.  (This study, like Johnstone et al., used only one rater for 
Hamilton scores, and apparently doubled the scores of that person). 
Thus, there is only scant evidence that ECT might be effective in the short-term for one of 
its major target groups – depressed women; and none that it is effective beyond the end of 
treatment for them. The 170-page report conducted for the UK’s National Health Service 
concluded ‘The evidence did not allow any firm conclusions to be drawn regarding the 
efficacy of ECT in …. women with psychiatric problems.’ (Greenhalgh et al., 2005, p. X) 
 
Age 
The average age of ECT recipients is usually between 60 and 65 (Leiknes et al., 2012; Read 
et al., 2013; 2018). One would assume that studies and meta-analyses would therefore pay 
particular attention to older people. However, with the exception of the smallest study (Harris 
& Robin), the average age of the samples ranged from 35 to 54, and some had no patients at 
all over 60, or 65 (see Table 1). No analyses by age were conducted by any of the studies.  
One study did report individuals’ ages and outcomes (Lambourn & Gill). The six people 
aged 60 or older who received ECT had a mean fall in Hamilton scores of 16.7, while the 10 
aged under 60 had nearly double the improvement (32.0), a large, but non-significant, 
difference (t (14) = 1.77, p = 0.09).  Improvement in the under 60s was, on average, 10.3 
points greater in the ECT group than in the SECT group. In the 60 or over group 
improvement was an average of 8.7 points greater in the SECT group than the ECT group. 
Six of the ten under 60s, but none of the 60 or older group, scored a 3 on the 0 - 3 doctors’ 
scale, a significant difference (X2 = 5.76, p = .016).  
One meta-analysis (Kho et al.) found no difference between patients over and under 65 (p. 
143) (based on 15 ECT samples in studies without SECT groups). An additional meta-
analysis, a Cochrane review, reported specifically on the effectiveness of ECT for the 
36 
 
‘depressed elderly’ (van der Wurff et al., 2003). It identified only one study comparing ECT 
and SECT (O’Leary et al., 1994). This was a re-analysis of data for the 35 people aged over 
65 in the Gregory et al. study. Twelve of the 35 had been withdrawn before completion of the 
study and the reviewers identified additional ‘major methodological shortcomings’ before 
deciding that ‘None of the objectives of this review could be adequately tested because of the 
lack of firm, randomised evidence” (p. 2).’ 
The UK ECT Group similarly concluded: 
Despite the reputation of ECT for efficacy in older patients, elderly people tend 
to be under-represented in trials, which limits the confidence with which results can be used 
to lend support to clinical practice in this subgroup. (p. 806) 
 
Greenhalgh et al. (2005) concurred, with: ‘The evidence did not allow any firm conclusions 
to be drawn regarding the efficacy of ECT in older people.’ (p. X) 
Thus, there is no evidence that ECT is effective for another of its major target groups – the 
depressed elderly, either in the short or longer term. Use with this group is especially 
problematic because it is well established that older people are particularly likely to develop 
memory loss as a result of ECT (Mosti & Brook, 2019; Sackeim et al., 2007). 
 
Adolescents 
No adolescents were included in any of the studies. There is no placebo controlled evidence 
that ECT is, or is not, effective for this group, either in the short or longer term.  
 
Involuntary Patients 
Many ECT recipients are given it against their will; about 40% in England (Read et al., 
2018). None of the studies or meta-analyses addressed the issue of whether the trauma of 
being forced to undergo ECT after stating that you do not want it reduces the probability of a 
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positive outcome. The UK government’s report noted that even what they considered to be 
the best of the meta-analyses (UK ECT Group) ‘did not identify any trials that explored … 
the impact of consumer choice on the outcomes of ECT’ (Greenhalgh et al. p. 15) 
Six of the 11 studies made no mention of whether some participants were being coerced to 
have ECT against their will, or even whether participants gave consent to take part in the 
study (Brill et al., Fahy et al.; Freeman et al.; Harris & Robin; Ulett et al.; Wilson et al.). 
These studies included most or all patients given ECT in a particular hospital and therefore 
almost certainly included some patients detained under mental health legislation and/or given 
ECT against their will. Wilson et al. refer to the withdrawal of ‘a voluntary patient signed out 
by husband’ implying that some participants were involuntary. Two studies reported that 
participants gave consent for the study but made no mention of whether some participants 
were being coerced to have ECT (Lambourn & Gill; West). Three studies explicitly excluded 
people who were being treated under the Mental Health Act or were been given ECT against 
their expressed wish (Brandon et al.; Gregory et al.; Johnstone et al.).  
Only one of the five studies that found no difference between ECT and SECT, therefore, 
had excluded people who were having ECT against their will, but the three studies that did 
make this an exclusion criterion produced positive findings. Thus, it is possible that ECT is 
even less effective under compulsion than when undertaken voluntarily. This makes intuitive 
sense, but the evidence is weak. It is all we have to go on, as none of the studies that did 
include coerced patients analysed their outcomes separately; and those later studies that (for 
sound ethical reasons) excluded coerced patients could not answer the question. 
What can safely be concluded is that there is no evidence that ECT is effective for coerced 
patients, either in the short or longer term. This is perhaps the most alarming of all our 
specific findings. To administer a treatment involving multiple use of general anaesthesia, 
multiple electric shocks and multiple grand mal convulsions, against someone’s will, is 
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unethical. To do so even in the absence of any evidence that there is a good chance of a 
positive outcome is especially alarming. We have no idea whether this treatment works under 
compulsion. To do so, therefore, is clearly both unscientific and unethical.  
 
Unilateral vs Bilateral 
The purpose of the current review is to determine whether the meta-analyses were correct to 
claim that ECT is, in general, more effective than SECT, not to compare different types of 
ECT. We should nevertheless report that only two of the 11 studies used unilateral electrode 
placements. All the participants in the Lambourn & Gill were administered unilateral ECT, 
which produced the same outcomes as SECT at the end of treatment and at follow up. In the 
Gregory et al. study both unilateral and bilateral placement produced significantly better 
outcomes than SECT at the end of treatment, but no meaningful follow up occurred. 
Therefore, the millions of administrations of unilateral ECT over the past 35 years (Leiknes 
at al., 2012), since the 1985 Gregory et al. study, have been based on one positive and one 
negative finding in the short term and one negative finding at follow up. 
 
Placebo 
Hope is a powerful placebo factor in psychiatric treatments, biological or psychological. It 
effects doctors, nurses, patients and their loved ones. It can influence not just perceptions of 
recovery but actual recovery. In the 1940s psychiatrists were excited about the new treatment. 
Hope of recovery had returned to some of the most depressing of institutions. Neurologist 
John Friedberg suggested that in those early days ‘the influence of ECT was on the minds of 
the psychiatrists, producing optimism and earlier discharges’ (Friedberg, 1976).  
39 
 
Almost all the 11 SECT studies found that having a series of general anaesthetic 
procedures in the belief that you are having a major medical procedure that the doctors and 
nurses believe in can temporarily improve mood. Some of the researchers commented on this:  
One possibility is that the effective therapeutic component of ECT is the repeated rapid induction 
of unconsciousness in the patient. … It could very well be that the primary therapeutic agent is the 
psychological meaning of the treatment to the patient. … The influence of the unusual amount of 
care and attention which all receive could be studied further. (Brill et al. p. 633). 
 
Effectiveness … is due in large part to the attendant procedures associated with, the administration 
of an anaesthetic and the mystique associated with an unusual form of treatment.  (Lambourn & 
Gill, p. 519).  
 
The results confirm that many depressive illnesses although severe may have a favourable 
outcome with intensive nursing and medical care even if physical treatments are not given’. 
(Johnstone et al., p. 1319) 
 
Brandon et al., (1984, p. 23) noted that an early version of convulsive therapy had been 
abandoned because it was no better than placebo: 
If the undoubted beneficial effects of electroconvulsive therapy were due to an elaborate placebo 
response the treatment would be comparable with insulin coma therapy, in which Ackner et al had 
shown that any effects were not due to the induction of coma with insulin. The absence of a 
specific antidepressant effect would provide a strong case for abandoning electroconvulsive 
treatment.  
 
A review focussing just on the placebo response with ECT (Rasmussen, 2009) found ‘an 
unexpectedly high rate of response in the sham groups’ and concluded ‘The modern ECT 
practitioner should be aware that placebo effects are commonly at play’ (p. 59). Furthermore: 
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It is recognized that through a complex set of circumstances related to the meaning a patient 
ascribes to encounters with health care providers, which are influenced by cultural factors, 
individual life experiences, education, and the manner in which doctors communicate, expectations 
develop in the mind of the patient which by themselves can result in measured improvement in the 
condition at hand. … Finally, one also should not discount the effect of the natural history of 
depressive episodes. In none of the studies was there an untreated, natural history control group. 
Patients tend to get better on their own, even without treatment. (p. 58) 
 
Lambourn and Gill reiterated that last, crucially important but often ignored, point: 
The contribution of spontaneous remission during this study remains an unknown factor because 
of the lack of a totally untreated group. (p. 515) 
 
Does Including Participants who have had ECT before a Study Un-blind the Study and 
thereby exaggerate ECT Superiority over SECT? 
Only one study (Lambourn & Gill) provides data that can test the hypothesis that having 
previously had ECT un-blinds participants because they know that ECT is always followed 
by headaches and disorientation and, therefore, know if they have had ECT in a study. 
Among the 16 people in the SECT group, the ten who had had one or more previous courses 
of ECT improved less (20.3 Hamilton points) than the six who had never had it before (27.2). 
Furthermore, the number of previous courses of ECT was related to degree of improvement 
on the Hamilton scale (r = 0.51; p = .044). So greater familiarity with the immediate adverse 
effects of ECT reduced the probability of benefitting from the placebo effects of SECT 
because they were more likely to know they had not received ECT.  Analysing just the data 
for the 11 people who had never had ECT before shows that the SECT group had slightly 
more improvement (27.2 points; sd = 17.2) than the ECT group (20.0; sd = 17.0). Analysing 
the data for the 25 who had had ECT previously shows the opposite, with the ECT group 
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improving more (29.1 points; sd = 18.3) than the SECT group (20.3; sd = 23.2). This suggests 
that by not excluding people who have previously had ECT all 11 studies exaggerated the 
difference between ECT and SECT in ECT’s favour, and that none were truly blind studies.  
  
Cost-Benefit analysis 
The fact that we don’t know whether ECT has any short- or long-term benefits must be 
weighed against what we do know about its adverse effects, which are summarised briefly.  
 
Brain damage and memory dysfunction.  Although ECT has a range of adverse 
psychological and emotional effects (Johnstone, 1999), the best documented findings are that 
ECT causes both major types of memory loss: anterograde amnesia (inability to retain new 
information) and, more commonly, retrograde amnesia (loss of memory for past events). 
A 2003 review identified four studies of memory loss at least six months post-ECT (n = 
597), and found a frequency range of 51% to 79%, and a weighted average of 70% (Rose, 
Wykes, Leese, Bindmann, & Fleischmann, 2003). Four studies (n = 703) found a range for 
‘persistent or permanent memory loss’ of 29% to 55%, with a weighted average of 38% 
(Rose et al., 2003). In 2007 ECT proponent Professor Harold Sackeim and colleagues 
conducted the largest prospective study to date and found that autobiographical memory was 
significantly worse than pre-ECT levels (p < .0001) six months later (Sackeim et al., 2007). 
Degree of impairment was significantly related to number of treatments. Even with the 
conservative cut off of two standard deviations worse than pre-ECT scores, 12% had ‘marked 
and persistent retrograde amnesia’, with higher rates for the two demographic groups who 
receive ECT disproportionately - women and older people. Impairment was also greater 
among those who received bilateral ECT rather than unilateral ECT.   
The most recent review (Mosti & Brook, 2019, p. 153) concludes that: 
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Recent meta-analyses suggest the most prominent deficits are on measures of attentional/executive 
control (ie, tests measuring cognitive flexibility, inhibitory control, and processing speed) and 
auditory verbal learning/recall (ie, unstructured list learning), a memory task that is also strongly 
correlated with executive functioning. 
 
ECT proponents often argue that these adverse effects are caused by depression not ECT 
(Read & Bentall, 2010, p. 343; Read, Cunliffe, Jauhar, & Mcloughlin, 2019), but a 2006 
review concluded that ‘There is no evidence of a correlation between impaired 
memory/cognition after ECT and impaired mood, much less a causal relationship’ (Robertson 
& Pryor, 2006, p. 230). The Sackeim et al. (2007) study confirmed that conclusion.  
A New Zealand Government report stated ‘ECT may permanently affect memory and 
sometimes this can be of major personal significance’ and noted the ‘slowness in acceptance 
by some professional groups that such outcomes are real and significant in people’s lives’ 
(Ministry of Health, 2004, p. 16). The American Psychiatric Association (2001) has admitted 
‘In some patients the recovery from retrograde amnesia will be incomplete, and evidence has 
shown that ECT can result in persistent or permanent memory loss’. 
Sadly, the severity and significance of the brain damage and memory loss is rarely studied. 
It is not hard, however, to find hundreds of personal accounts of debilitating levels of 
disruption to people’s lives. See, for example: https://ectjustice.com/ect-survivor-stories/ and 
https://www.madinamerica.com/2016/04/comments-by-shock-survivors-and-their-loved-
ones/. 
A recent USA class action lawsuit was settled on eve of trial at a Federal Court, which had 
ruled ‘A reasonable jury could find that the ECT device manufacturer failed to warn 
plaintiffs' treating physicians of brain damage resulting from ECT’ (Breggin, 2018; 
Schwartzkopff, 2018). The manufacturer, Somatics, immediately issued a Regulatory Update 




‘Brain damaging therapeutics’  
The UK ECT Group found that bilateral ECT produces greater cognitive impairment than 
unilateral. Gregory et al. also discuss the ‘undoubtedly greater memory impairment produced 
by bilateral ECT’ (p. 523). The 170 page review by Greenhalgh et al. (2005) concluded that 
any gains of using bilateral rather than unilateral ECT ‘are achieved only at the expense of an 
increased risk of cognitive side-effects” (p.1). 
If the modest, temporary effects on depression are only to be found if the shock is passed 
across both temporal lobes, thereby causing maximal memory loss, this would confirm the 
early theories about how ECT works. Early post-mortem examinations had led to the article 
‘Brain damaging therapeutics,’ where the psychiatrist who introduced ECT to the US wrote, 
‘The greater the damage the more likely the remission.  … Maybe it will be shown that a 
mentally ill patient can think more clearly and more constructively with less brain in actual 
operation’ (Freeman, 1941). A colleague had explained: ‘There have to be organic changes or 
organic disturbances in the physiology of the brain for the cure to take place. I think the 
disturbance in memory is probably an integral part of the recovery process’ (Myerson, 1942).  
A review (involving JR) of the effects of ECT on the brain put it this way: 
We suggest that the temporarily improved scores on depression instruments following ECT reflect 
the combination of frontal and temporal lobe functional impairments and activation of the HPA 
axis and the mesocorticolimbic dopamine system. These effects as well as other detailed changes 
observed in structures such as the hippocampus appear consistent with those typically seen after 
severe stress-exposure and/or brain trauma. (Fosse & Read, 2013, p. 6) 
 
Mortality rates. The idea that the mortality rate is ‘1 per 10,000 patients or 1 per 80,000 
treatments’ has been promulgated, without supporting evidence, by psychiatric associations 
(A.P.A. 2001; R.C.P., 2017) and the USA’s Food and Drug Administration (2011). A recent 
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study put it even lower, at ‘2.1 per 100,000’ treatments (Tørring, Sanghani, Petrides, Kellner, 
& Østergaard, 2017); but this was based on medical records (relying on staff recording that 
they had caused a death). Numerous studies (see Read & Bentall, 2010; Read et al., 2013) 
have found mortality rates many times greater than these claims. For example, of 8,148 ECT 
recipients in Texas, seven died within 48 hours (Shiwach, Reid, & Carmody, 2001). 
Excluding the two which the researchers argued were ‘unlikely to have been related to ECT’ 
this is one per 1,630. Eight more died within two weeks, of ‘cardiac event’ (the most 
common ECT-related cause of death). If these are included the rate becomes one per 627. 
When researchers wanted to interview 183 people, one year after ECT, it was reported that 
two (one in 91.5) had died during the ECT (Freeman & Kendell, 1980). A 1980 study 
(relying on British psychiatrists’ reports of deaths from the ECT they had administered) 
found that four out of 2,594 ECT patients had died within 72 hours (one per 648.5) (Pippard 
& Ellam, 1981).  It could not be determined whether the one death (four days post-ECT) 
among 75 French ECT recipients was ECT-related. This study, by anesthetists, found 
‘potentially life-threatening’ complication’ for 12 (16%) (Tecoult & Nathan, 2001).   
The oft repeated claim that ECT causes no more deaths than general anaesthesia 




The major limitation of any review designed to determine whether ECT works is the low 
quantity and poor quality of the available studies. The goal of the current review, however, is 
different; to evaluate the quality of the studies and of the meta-analyses that cite them.   
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Given the small number of studies, caution should be exercised when interpreting non-
significant t-tests involving the 11 studies, which might have been significant had there been 
more studies.  
 
Conclusions 
The scarcity and poor quality of most of the findings suggesting that ECT has short term 
benefits for some depressed people, the complete lack of evidence of long term benefits, and 
the absence of evidence that it prevents suicide, means, together with the high risk of 
permanent memory loss and small increased risk of death, broadly confirms the conclusions 
of previous reviews (Read & Bentall, 2010; Read et al., 2013; Read & Arnold, 2017; Ross, 
2006) and books (Andre, 2008; Breggin, 2008). For example (Read & Bentall, 2010): 
Given the strong evidence of persistent and, for some, permanent brain dysfunction, primarily 
evidenced in the form of retrograde and anterograde amnesia, and the evidence of a slight but 
significant increased risk of death, the cost-benefit analysis for ECT is so poor that its use cannot 
be scientifically justified. (p. 333). … The very short-term benefit gained by a small minority 
cannot justify the significant risks to which all ECT recipients are exposed. (p. 344)  
 
Perhaps, however, given the outcome of this first ever analysis of the quality of the eleven 
studies that have attempted to determine if ECT is better than placebo, a more accurate 
conclusion, rather than ‘a very short-term benefit gained by a small minority’ is that we just 
don’t know whether ECT is better than, worse than, or no different from, placebo.  
What can the 11 SECT studies tell us about seven specific sub groups? Firstly, we can 
reasonably conclude that there is no rigorous evidence whatsoever that ECT has any benefit 
for the three conditions for which it is primarily recommended today: (i) severely depressed 
people, (ii) acutely suicidal people and (iii) people for whom antidepressants and/or 
psychological therapies do not work. Women and older people are the target demographics 
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for ECT in the 21st century, but there is hardly any specific evidence that ECT is better than 
SECT for (iv) women, in the short-term, and none regarding the long term, plus women are 
particularly likely to suffer long term memory loss. There is no evidence whatsoever that 
ECT is superior to SECT in (v) older people, who are also differentially susceptible to 
memory loss. There is no evidence that ECT is effective (vi) when given under compulsion, 
as it so often is. There is also no evidence that it is effective for (vii) adolescents.  
Our conclusions regarding depression parallel those of a recent commentary on Cochrane 
reviews of ECT for ‘schizophrenia’ (Shokraneh, Sinclair, Irving & Aali, 2019):   
What is common in all versions of these Cochrane reviews is that in spite of seven decades of 
clinical use of ECT for people with schizophrenia, there still is a lack of strong and adequate 
evidence regarding its effectiveness and the question ‘should we stop using electroconvulsive 
therapy?’ is currently unanswered for people with schizophrenia.  
 
The remarkably poor quality of the research in this field, and the uncritical acceptance of 
that research by psychiatry’s meta-analyses, and its professional bodies, all of which endorse 
ECT as an effective and safe treatment, is a sad indictment of all involved, and a grave 
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Any statement or evidence that the study was randomised, and no evidence 
that this was not the case  
   process described Any description of the randomisation process 
BLINDED C 
 
Any statement or evidence that the study was blinded, and no evidence that 
the blind was broken - for raters or patients 
   method tested Any evidence that the blinding of either the raters or patients was tested  
   no previous  ECT None of the participants had had ECT at any time prior to the study 
ALL DEPRESSED 
 
All participants (or a clear subset with separate data) were adjudged, by any 
method, to be depressed (with or without other features, eg psychosis)  
   reliable  diagnosis Diagnosis made by two or more independent people, or any standardised 
depression assessment tool, i.e. not just by one clinician/clinical diagnosis 
with unspecified diagnoser(s) 
   severe  
 
All participants severely depressed at outset of study, either any meaningful 
description of ‘severe’, or < 22 on Hamilton (44 if two raters, most studies), 
< 29 on Beck scale)  
FULL ECT COURSE  At least six ECTs or 6 SECTs; so excluding studies giving ECT to SECT 
group before six treatments 




eg Hamilton, Montgomery, Beck 
  Means & SDs Means and SDs (or SEs or SEMS) reported for the depression scales pre 
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PATIENT RATINGS Any self-report or patient ratings administered and scores reported 
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Any ‘Quality of Life’ ratings administered and scores reported (eg 
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1 RATER TYPE 
More than one type/group of persons making separate ratings; e.g. 
psychiatrists, nurses, patients, etc. 
DECLINERS 
DESCRIBED C 
Any description of people who were approached but declined to participate 
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BOTH ECT & SECT 
SAMPLES < 10 
Both sample sizes (ECT and SECT) 10 or larger  
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FOLLOW UP DATA Any outcome data gathered beyond end of treatment (more than one day 
after last ECT), without ECT being given to the SECT group 
 
* YES = clear affirmative evidence; NO = no evidence or clear negative evidence. 
C = Relates to a Cochrane ‘risk of bias’ domain; either directly, or for decliners and 
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1 graphs show difference is  even smaller for staff than for doctors 
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3 Individual scores for each person given so means could be calculated 
4 rated 3 on a 0-3 scale 
5 Significant only for ‘deluded’ and ‘retarded’ subgroups  
6 Means and SDs reported by Buchan et al. (1992) 
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1 ‘some patients in the nonshock group believed that they were receiving some new variation 
of ECT’ 
2  patients and observers knew which treatment had been administered 
3 one of the raters not blind 
4 patients ‘blindness’ tested; raters not 
5 percentage having had ECT prior to the study not reported 
6 ‘Moderate severity’. ‘Severe depression with high suicidal risk were not included’ 
7  average baseline Beck scores in ‘moderate’ depression range 
8  gave ECT to SECT group after 4 ECTs 
9 gave ECT to SECT group after 2 ECTs 
10 means and SDs represented in figure and published by Buchan et al (1992) 
11 means but no SDs 
12 self-rating scale administered but not reported 
13  gender and age not recorded 
14  not valid because sample mostly not depressed 
15 data gathered but only five days after last treatment 




TABLE 4. Summaries of the 5 Meta-analyses of SECT vs ECT Studies 
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2003   
6 studies 
n = 2261 




n = 245 




n = 77 
Ulett et al 1956 
(2) 
X2 = 6.36 *2 
 
EX EX OR = .57 EX 
Brill et al 1959 
(2) 
X2 = 2.37 
 
EX EX OR = 3.82 EX 
Harris & Robin 1960 
(2) 
X2 = 0.67 
 
EX EX OR = 17.0 EX 
Fahy et al 1963 
(2) 
X2 = 1.09 
 
EX EX OR = 3.76 EX 
Wilson et al 1963 
(1) 
EX EX ES = 1.08 EX EX 
Freeman et al 1978 
(1) 
EX EX ES = 0.63 EX EX 
Lambourn & Gill 78 
(4) 
X2 = 0.12 
 
ES 0.09 ES = 0.17 OR =1.00 EX 
Johnstone et al 1980  
(1) 
EX EX ES = 0.74 * EX EX 
West 1981  
(3) 
X2 = 14.85 * EX ES = 1.25 * OR = 86.1* EX 
Brandon et al 1984 
(3) 
EX ESs =  
1.38 - 1.99 * 
 
EX OR = 2.16 Included, 
no data 
Gregory et al 1985 
 (2) 
EX 4 EX SES = 1.42 * EX EX 
Overall finding of 
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72% v 40%  
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(but see note 2) 
Pooled Effect 







Size  = 0·91 




OR 2.83  [CI 
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High dose    
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Low dose  
  unilateral 6 = 2.74 
Bifrontal 6 = 3.39 
2/4 types significant 
* statistically significant finding 
EX = study excluded by meta-analysis 
OR = odds ratio between ECT and SECT 
ES = standardised effect size 
1 reported as 256 by UK ECT Group, by including withdrawers during 4 of the studies 
2  wrongly included photoshock data, without which the finding is nonsignificant 
3 ‘translates to’ a mean Hamilton difference of 9.7 (95% CI 5.7-13.5) 
4 same year as the meta-analysis so possibly not published in time 
5 extrapolated from one ECT-SECT study (Brandon et al.) and multiple other (not ECT-SECT) 
studies 
6 no data in the only ECT-SECT study (Brandon et al.) to directly support these ORs (see text) 
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3 literature reviews;   
3 magnetic stimulation articles;  
1 meta-analysis for older people 
only;   
1 meta-analysis in Hungarian; 
1 paper on statistical analyses re.    
   depression and ECT 5 meta-
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for review 
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